The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Abstract
Commercially available lipid formulations of amphotericin B (Abelcet, Amphotec, and AmBisome) represent a significant advance in drug delivery technology. Differences in biochemical, pharmacokinetic, and pharmacodynamic properties among the lipid products have been shown in in vitro and in vivo models. Clinical experience with these products has been primarily in patients either refractory to or intolerant of conventional amphotericin B deoxycholate (AmBd). None of the lipid-based products demonstrates superior efficacy when prospectively compared with AmBd in the treatment of documented infections. When used for the empirical treatment of febrile neutropenia, AmBisome significantly reduced the incidence of proven emergent fungal infections but did not improve short-term survival rates, in comparison with AmBd. Acute infusion-related adverse events vary, whereas nephrotoxicity is reduced with all three lipid formulations. Until superior efficacy is clearly shown (for documented infections) or pharmacoeconomic analyses document the value of these drugs, use of such expensive agents should be highly restricted to those who are intolerant of or refractory to AmBd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., et al. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.704 · Cited by 405
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M. A., Gorin, N. C., Klastersky, J., Fenaux, P., et al. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.73 · Cited by 280
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial
Meunier, F., Prentice, H. G., & Ringden, O. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.83 · Cited by 247
Distribution and Activity of Amphotericin B in Humans
Christiansen, K. J., Bernard, E. M., Gold, J. W. M., & Armstrong, D. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/152.5.1037 · Cited by 229
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., & Tate, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223
Chemotherapy of Systemic Mycoses
Bennett, J. E. (1974) · New England Journal of Medicine · doi:10.1056/nejm197401032900107 · Cited by 220
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Frankel, L. S., & Mehta, K. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.310 · Cited by 216
Sharkey, P. K., Graybill, J. R., Johnson, E. S., Hausrath, S. G., Pollard, R. B., Kolokathis, A., Mildvan, D., Fan-Havard, P., Eng, R. H. K., Patterson, T. F., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.315 · Cited by 197
Tollemar, J., Höckerstedt, K., Ericzon, B.-G., Jalanko, H., & Ringdén, O. (1995) · Transplantation · doi:10.1097/00007890-199501150-00009 · Cited by 179
Use of liposomes as injectable-drug delivery systems
Ostro, M. J., & Cullis, P. R. (1989) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/46.8.1576 · Cited by 177
Mills, W., Chopra, R., Linch, D. C., & Goldstone, A. H. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04825.x · Cited by 171
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J., Cantor, A. B., Gurwith, M., Mond, C. D., Mamelok, R. D., & Bowden, R. A. (1997) · PubMed · Cited by 166
Tollemar, J. G., Ringdén, O. T. H., Andersson, S., Sundberg, B., Ljungman, P. T., & Tydén, G. (1993) · PubMed · Cited by 162
Amphotericin B lipid complex therapy of experimental fungal infections in mice
Clark, J. M., Whitney, R. R., Olsen, S. J., George, R. J., Swerdel, M. R., Kunselman, L., & Bonner, D. P. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.615 · Cited by 159
Invasive fungal sinusitis in patients undergoing bone marrow transplantation.
Drakos, P., Nagler, A., Or, R., Naparstek, E., Kapelushnik, J., Engelhard, D., Rahav, G., Ne'emean, D., & Slavin, S. (1993) · PubMed · Cited by 157
The Safety and Efficacy of Amphotericin B Colloidal Dispersion in the Treatment of Invasive Mycoses
Oppenheim, B. A., Herbrecht, R., & Kusne, S. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1145 · Cited by 146
Ng, T., & Denning, D. W. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430100129015 · Cited by 134
Gregoriadis, G. C. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.39 · Cited by 129
Janoff, A. S., Perkins, W. R., Saletan, S., & Swenson, C. E. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150730 · Cited by 122
Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS
Coker, R. J., Viviani, M. A., Gazzard, B., Pont, B. D., Pohle, H. D., Murphy, S. M., Atouguia, J., Champalimaud, J. L., & Harris, J. R. W. (1993) · AIDS · doi:10.1097/00002030-199306000-00011 · Cited by 119
Bowden, R. A., Cays, M., Gooley, T. A., Mamelok, R. D., & van Burik, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117
Gotzsche, P. C., & Johansen, H. (1997) · BMJ · doi:10.1136/bmj.314.7089.1238 · Cited by 105
Liposomes as carriers of antimicrobial agents
Lopez‐Berestein, G. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.5.675 · Cited by 101
Lopez‐Berestein, G., Rosenblum, M. G., & Mehta, R. T. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.199 · Cited by 95
Patterson, T. F., Miniter, P., Dijkstra, J., Szoka, F. C., Ryan, J. L., & Andriole, V. T. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.4.717 · Cited by 93
Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
Perkins, W. R., Minchey, S. R., Boni, L. T., Swenson, C. E., Popescu, M. C., Pasternack, R. F., & Janoff, A. S. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90414-h · Cited by 87
Allende, M. C., Lee, J. W., Francis, P., Garrett, K. F., Dollenberg, H., Berenguer, J., Lyman, C. A., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.518 · Cited by 70
Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin.
Ringdén, O. T. H., Andström, E. E., Remberger, M., Svahn, B.-M., & Tollemar, J. G. (1994) · PubMed · Cited by 68
Anaphylactic reactions to liposomal amphotericin
Laing, R. B. S., Milne, L. J. R., Leen, C. L. S., Malcolm, G. P., & Steers, A. J. W. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92116-4 · Cited by 68
Liposomes: Realizing Their Promise
Bangham, A. D. (1992) · Hospital Practice · doi:10.1080/21548331.1992.11705537 · Cited by 66
Hostetler, J. S., Clemons, K. V., Hanson, L. H., & Stevens, D. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2656 · Cited by 59
Clemons, K. V., & Stevens, D. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1829 · Cited by 57
Lackner, H., Schwinger, W., Urban, C., MÜLLER, W., Ritschl, E., Reiterer, F., Kuttnig-Haim, M., Urlesberger, B., & Hauer, C. (1992) · PEDIATRICS · doi:10.1542/peds.89.6.1259 · Cited by 55
Ericsson, M., Anniko, M., Gustafsson, H., Hjalt, C. A., Stenling, R., & Tärnvik, A. (1993) · Clinical Infectious Diseases · doi:10.1093/clind/16.4.585 · Cited by 53
Limited Toxicity of Prolonged Therapy with High Doses of Amphotericin B Lipid Complex
Kline, S., Larsen, T., Fieber, L. A., Fishbach, R., Greenwood, M. F., Harris, R. C., Kline, M. W., Tennican, P. O., & Janoff, E. N. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1154 · Cited by 37
Wasan, K. M., & Lopez‐Berestein, G. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.5.1126 · Cited by 35
Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia
Arning, M., Heer‐Sonderhoff, A. H., Wehmeier, A., & Schneider, W. (1995) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02112616 · Cited by 34
Phagocyte Transport as Mechanism for Enhanced Therapeutic Activity of Liposomal Amphotericin B
Mehta, R. T., McQueen, T. J., Keyhani, A., & Lopez‐Berestein, G. (2009) · Chemotherapy · doi:10.1159/000239202 · Cited by 34
Joly, V., Bolard, J., Saint-Julien, L., Carbon, C., & Yéni, P. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.262 · Cited by 34
Conventional vs. Liposomal Amphotericin B in Immunosuppressed Children
Zoubek, A., Emminger, W., Schmidmeier, W., Peters, C. A., Pracher, E., Grois, N., & Gadner, H. (1992) · Pediatric Hematology and Oncology · doi:10.3109/08880019209018337 · Cited by 34
Sodium Loading Treatment for Amphotericin B-Induced Nephrotoxicity
Gardner, M. L., Godley, P. J., & Wasan, S. M. (1990) · DICP · doi:10.1177/106002809002401006 · Cited by 27
High cure rate of invasive fungal infections in immunocompromised children using ambisome.
Ringdén, O. T. H., Tollemar, J. G., Dahllöf, G., & Tydén, G. (1994) · PubMed · Cited by 19
SILVA, L. P. D., Amaral, J. M. V., & FERREIRA, N. C. (1993) · PEDIATRICS · doi:10.1542/peds.91.6.1217a · Cited by 14
Cited by
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 688
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Drug delivery strategies for poorly water-soluble drugs
Fahr, A., & Liu, X. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.403 · Cited by 568
Metadata
- Authors
- Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-09-01
- Volume
- 27
- Issue
- 3
- Pages
- 603-618
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1978263354
- Cited by
- 395
- References
- 46
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.